Julius Clinical Expands CNS and Cardiometabolic Capabilities with Post-Merger Growth and New Operations in Spain and Germany

ZEIST, The Netherlands, Sept. 3, 2025 /PRNewswire/ -- Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key therapeutic areas during the second quarter of 2025. This growth follows the company's successful merger with Peachtree BioResearch Solutions announced on May 14th, 2025, combining two organizations with complementary CNS expertise and expanding operational reach across the United States and Europe.

The merged entity's integrated capabilities and established track record have attracted strong interest from biotech and mid-sized pharmaceutical companies. Julius Clinical's heritage in CNS and Cardiometabolic indications, supported by operational teams strategically located in the US and EU, has been a decisive factor in securing new clinical study awards.

Kristy Nichols, President, North America of Julius Clinical, commented: "At Julius Clinical, we're not just executing trials; we're leading the evolution of therapeutic development. Our merger with Peachtree BioResearch Solutions has unlocked a new era of scale, agility, and therapeutic depth, especially in CNS and Cardiometabolic indications. Customers are choosing us because we understand science, anticipate the challenges, and deliver with precision across borders, and that's what sets us apart."

In parallel with its therapeutic growth, Julius Clinical has expanded its geographical footprint with the establishment of operations in Spain and Germany. Spain and Germany have long been strategic clinical trial destinations for Julius Clinical with over 70 clinical trials completed in Spain and Germany. This investment will strengthen the company's local regulatory and clinical operations capabilities in two of Europe's most active and high-quality clinical trial markets.

Ricard Quingles, Chief Business Officer, Julius Clinical commented: "Spain and Germany are essential not only to European clinical research but also globally. Their innovation- driven ecosystems, world-class research centers, and highly skilled professionals make them ideal hubs for high-quality clinical trials. By establishing local operations, Julius Clinical enhances patient access, accelerates study delivery, and strengthens our commitment to supporting biotech and pharma partners worldwide."

About Julius Clinical

Founded in 2008 and headquartered in Zeist, The Netherlands, Julius Clinical is a leading clinical CRO specializing in central nervous system, cardio-metabolic, renal, and rare diseases. With over 380 clinical trials and 220,000+ subjects across 39 countries, Julius Clinical combines scientific leadership, operational excellence, and a global network of research sites to deliver tailored solutions for biotech- and midsized pharma customers. For more information, visit https://www.juliusclinical.com or follow us on LinkedIn.

SOURCE Julius Clinical